- Targeting Activin E may represent a novel therapeutic strategy for metabolic dysfunction-associated steatohepatitis (MASH) and obesity‑related metabolic dysfunction - ARO-INHBE produced meaningful reductions in liver fat content as a monotherapy or in combination with low-dose tirzepatide in
- New data support potential use of plozasiran without dose adjustment in patients with moderate-to-severe renal or moderate hepatic impairment - Case report suggests that preconception exposure to plozasiran may be associated with sustained lowering of fasting triglyceride levels throughout the
- Conference Call and Webcast Today, May 7, 2026, at 4:30 p.m. ET PASADENA, Calif. --(BUSINESS WIRE)--May 7, 2026-- Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced financial results for its fiscal 2026 second quarter ended March 31, 2026.
- Precision approach targets patients who have a mutation in the PNPLA3 gene, which is highly prevalent among Hispanic patients with MASH - Phase 1 data published in The New England Journal of Medicine demonstrated a 46% reduction in liver fat in homozygous patients and a well-tolerated safety
PASADENA, Calif. --(BUSINESS WIRE)--May 4, 2026-- Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the following upcoming events: BofA Securities 2026 Healthcare Conference – May 12-14, 2026 Type: Investor Group Dinner Date/Time: May 12, 2026
– REDEMPLO is the first and only medicine approved for use in the treatment of FCS in Australia, and is authorized for both genetically confirmed and clinically diagnosed adult patients with FCS – People living with FCS have extremely high triglyceride levels and a substantially higher risk of
– If confirmed by the European Commission, REDEMPLO would be the first and only siRNA medicine authorized in the EU for both genetically confirmed and clinically diagnosed adult patients with FCS – People living with FCS have extremely high triglyceride levels and a substantially higher risk of
PASADENA, Calif. --(BUSINESS WIRE)--Apr. 20, 2026-- Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it will host a webcast and conference call on May 7, 2026, at 4:30 p.m. ET to discuss its financial results for the fiscal 2026 second quarter ended March 31, 2026.
– Patients with severe hypertriglyceridemia (sHTG) achieved an 83% median reduction in triglycerides (TG), with 96% of patients achieving TG levels below 500 mg/dL, a threshold associated with increased risk of acute pancreatitis – No adjudicated acute pancreatitis events occurred in any patient
PASADENA, Calif. --(BUSINESS WIRE)--Feb. 24, 2026-- Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the following upcoming events: TD Cowen 46th Annual Health Care Conference – March 2-4, 2026 Type: Fireside Chat Presentation Date/Time: March 2,
- Conference Call and Webcast Today, February 5, 2026, at 4:30 p.m. ET PASADENA, Calif. --(BUSINESS WIRE)--Feb. 5, 2026-- Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced financial results for its fiscal 2026 first quarter ended December 31, 2025.
- ARO-DIMER-PA is the first clinical candidate designed to silence the expression of two genes with a single RNAi molecule - In preclinical studies, ARO-DIMER-PA potently lowered serum PCSK9 and APOC3, and ameliorated high levels of non-HDL-cholesterol, LDL-cholesterol, and triglycerides in
PASADENA, Calif. --(BUSINESS WIRE)--Jan. 20, 2026-- Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it will host a webcast and conference call on February 5, 2026 , at 4:30 p.m. ET to discuss its financial results for the fiscal 2026 first quarter ended December 31, 2026 .
PASADENA, Calif. --(BUSINESS WIRE)--Jan. 7, 2026-- Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced the pricing of its concurrent public offerings of (i) $625,000,000 aggregate principal amount of 0.00% convertible senior notes due 2032 (the “notes”) and (ii) 3,100,776 shares of
- REDEMPLO is being launched in China by Sanofi - NMPA approval triggers $10 million milestone payment to be paid by Sanofi to Arrowhead subsidiary Visirna Therapeutics PASADENA, Calif. --(BUSINESS WIRE)--Jan. 7, 2026-- Arrowhead Pharmaceuticals, Inc.
PASADENA, Calif. --(BUSINESS WIRE)--Jan. 6, 2026-- Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced its intention to offer, subject to market and other conditions, $500 million aggregate principal amount of convertible senior notes due 2032 (the “notes”) and $200 million of common